China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Dec. 17 the first domestic anti-PD-1 mAb, Tuoyi toripalimab (JS001) from Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China), as second-line treatment of melanoma.

The news comes as Junshi is planning to price its IPO on the Hong Kong Stock Exchange this week (see "Junshi IPO on Deck in Hong Kong")...